Cargando…

New bortezomib-based combination therapy for elimination of myeloma cells

Detalles Bibliográficos
Autores principales:	Meister, S, Lang, V, Wissniowski, TT, Voll, RE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291714/ http://dx.doi.org/10.1186/1478-811X-7-S1-A34

Ejemplares similares

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

The role of a defective clearance in the pathogenesis of systemic lupus erythematosus
por: Franz, S, et al.
Publicado: (2004)

C/EBPbeta mediates bortezomib-induced EBV and KSHV lytic gene expression
por: O’Farrell, Courtney, et al.
Publicado: (2010)

EHMTI-0263. WHO step scheme into combination with a therapeutical local anesthesia (TLA), physiotherapy, TENs, phytotherapy, acupressure, acupuncture for chronically therapy resistant trigeminal neuralgia after Trang
por: Nguyen, T, et al.
Publicado: (2014)

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma
por: Wei, Daolin, et al.
Publicado: (2016)

Cost-effectiveness of early goal-directed therapy in the treatment of severe sepsis and septic shock
por: Huang, DT, et al.
Publicado: (2003)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy
por: Yun, Charles, et al.
Publicado: (2015)

Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma
por: Zhou, Liang
Publicado: (2022)

Effects of endotoxin elimination therapy using polymyxin B immobilized fiber in patients with septic shock after surgical operation
por: Ikeda, T, et al.
Publicado: (1997)

Expression and regulation of bone morphogenetic protein antagonists in vascular smooth muscle cells
por: Maciel, TT, et al.
Publicado: (2003)

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma
por: McClanahan, Alli, et al.
Publicado: (2022)

Carbon dioxide elimination during continuous venovenous hemodiafiltration (CVVHD)-laboratory experiment
por: Ruzicka, J, et al.
Publicado: (2000)

Positive and negative regulators of transforming growth factor beta 1/bone morphogenetic protein pathways are constitutively expressed in mesangial cells
por: Maciel, TT, et al.
Publicado: (2003)

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020)

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era
por: Wei, Min, et al.
Publicado: (2021)

STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models
por: Rozic, Gabriela, et al.
Publicado: (2018)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Elimination of rheumatoid synovium in situ by Fas ligand 'gene scalpel™'
por: Zhang, H, et al.
Publicado: (2001)

Organizational capacity to eliminate outcome disparities in addiction health services
por: Guerrero, Erick G, et al.
Publicado: (2015)

Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013)

Fcγ receptors complement interaction: new aspects in pathogenesis and treatment of vasculititis
por: Schmidt, RE
Publicado: (2003)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Arterial oxygen partial pressures during nitrous oxide and xenon elimination
por: Stahl, W, et al.
Publicado: (1998)

New therapies
por: Wofsy, David
Publicado: (2012)

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
por: Maekawa, Keiko, et al.
Publicado: (2019)

Prolonged benzodiazepine elimination in addicted patients as a reason of early post-detoxification relapses
por: Basinska, Anna, et al.
Publicado: (2010)

Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells
por: Staskiewicz, Anna, et al.
Publicado: (2023)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Hematopoietic stem cell transplantation in Multiple Myeloma. Experience of the Instituto Nacional de Cancerologia, Mexico
por: Bahena-Garcia, Magdalena, et al.
Publicado: (2007)

Effectiveness of a serious game for medical education on insulin therapy for diabetes: randomized controlled trial
por: Diehhl, Leandro Arthur, et al.
Publicado: (2015)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Combination therapy of atorvastatin and probucol on ischemic stroke in clinic
por: Yan, Tao, et al.
Publicado: (2012)

Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
por: Jagannath, Sundar
Publicado: (2009)

Targeting p53 by small molecule p53 activators in multiple myeloma
por: Saha, Manujendra N, et al.
Publicado: (2012)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

New Vectors and New Targets for Gene Therapy in Rheumatoid Arthritis
por: Jorgensen, C, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_cjmh3m3hitl3lk474plm1bn4kb